NBW Capital LLC Lowers Position in HealthEquity, Inc. (NASDAQ:HQY)

NBW Capital LLC lowered its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 11.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,163 shares of the company’s stock after selling 10,493 shares during the period. HealthEquity makes up 1.4% of NBW Capital LLC’s investment portfolio, making the stock its 27th largest position. NBW Capital LLC owned about 0.09% of HealthEquity worth $7,596,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Holocene Advisors LP purchased a new stake in shares of HealthEquity in the 3rd quarter valued at about $1,246,000. GSA Capital Partners LLP purchased a new stake in shares of HealthEquity in the 3rd quarter valued at about $638,000. Natixis Advisors LLC increased its position in shares of HealthEquity by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock valued at $17,122,000 after purchasing an additional 48,009 shares during the last quarter. Vaughan Nelson Investment Management L.P. increased its position in shares of HealthEquity by 36.7% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after purchasing an additional 226,563 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its position in shares of HealthEquity by 2.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company’s stock valued at $92,216,000 after purchasing an additional 24,665 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Analysts Set New Price Targets

HQY has been the topic of several recent research reports. BTIG Research increased their price objective on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Raymond James increased their price objective on HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday, February 25th. Royal Bank of Canada increased their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. The Goldman Sachs Group initiated coverage on HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price objective on the stock. Finally, JMP Securities increased their price objective on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, HealthEquity currently has an average rating of “Moderate Buy” and an average target price of $113.54.

Insider Activity

In other news, Director Stuart B. Parker sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total value of $2,418,000.00. Following the completion of the transaction, the director now owns 19,061 shares in the company, valued at $1,843,579.92. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $111.29, for a total value of $639,917.50. Following the completion of the transaction, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,000 shares of company stock worth $3,895,788 in the last quarter. 2.20% of the stock is owned by company insiders.

HealthEquity Price Performance

Shares of HQY stock opened at $104.82 on Tuesday. The firm has a market cap of $9.08 billion, a P/E ratio of 96.17, a P/E/G ratio of 1.60 and a beta of 0.55. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $115.59. The business’s 50 day moving average price is $105.13 and its 200-day moving average price is $93.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same period in the prior year, the business earned $0.40 earnings per share. On average, equities research analysts anticipate that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.